top of page

Dyne Therapeutics

    Approach: antibody-oligonucleotide conjugates

    Status: Phase 1/2

    Section of Dyne's website discussing myotonic dystrophy

    Video on Dyne's website explaining its technology

    Mar. 21, 2021 Patent Application

    Article on Dyne's technology

    Press Release on Dyne's launch

    April 3, 2019 Endpoints article on Dyne launch

    June 13, 2019 Press Release: Dyne Therapeutics Presents Nonhuman Primate Proof of Concept Data on FORCE™ Therapeutic Platform at International Myotonic Dystrophy Consortium Meeting (IDMC-12)

    September 14, 2019 Presentation at Myotonic conference (starts at 40:30)

    October 2019 abstract presented at World Muscle Society conference

    Aug. 25, 2020 S1 filed in conjunction with IPO (data within filing)

    Sept. 2020 Presentation at Myotonic Dystrophy Foundation annual conference (starts at 18:39)

    Jan. 10, 2021 Press Release detailing preclinical data

    Feb. 9, 2021 Myotonic Dystrophy Foundation presentation

    May 2021 Investor DM1 Program Webcast

    Oct. 2021 R&D day slides

    May 14, 2021 Press Release regarding data presented at ASGCT conference

    May 16, 2022 Press Release regarding data presented at ASGCT conference

    July 12, 2022 Press Release announcing CTA clearance to start P1/2 trial in New Zealand

bottom of page